Lee Danner & Bass Inc. Sells 170 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Lee Danner & Bass Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,461 shares of the medical equipment provider’s stock after selling 170 shares during the period. Lee Danner & Bass Inc.’s holdings in Zimmer Biomet were worth $224,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet in the first quarter valued at about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet during the first quarter worth about $30,000. Accent Capital Management LLC bought a new position in Zimmer Biomet during the first quarter worth about $35,000. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 305 shares during the last quarter. Finally, Zions Bancorporation National Association UT bought a new position in Zimmer Biomet during the first quarter worth about $48,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.0%

NYSE ZBH opened at $103.14 on Friday. The stock’s 50-day moving average is $101.86 and its 200-day moving average is $97.71. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The firm has a market cap of $20.43 billion, a P/E ratio of 25.09, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ZBH shares. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Friday. Canaccord Genuity Group restated a “hold” rating and set a $101.00 target price on shares of Zimmer Biomet in a report on Wednesday. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. BTIG Research raised their target price on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Finally, Evercore ISI reduced their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $111.94.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.